Biotek-snakken — September 2022
-
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study – ASCELIA
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...
(www.ascelia.com)
-
Ascelia Pharma med gode data i andet support studie også
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind